Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer/Pharmacia integration

This article was originally published in The Tan Sheet

Executive Summary

Pfizer Senior VP-Strategic Planning & Business Development Tom Booth will lead Consumer Healthcare division's transition team in the Pharmacia integration. Teams are responsible for "day-to-day transition planning process," serving as "focal point for two-way communication between the divisions and corporate and between the divisions themselves," says 1Pfizer employee newsletter article filed with SEC. Pfizer, Pharmacia team leaders will meet for first time Aug. 13. "Transition process will be carried out using Pfizer's existing governance structure, which went through a significant overhaul following the W-L merger, with more decision-making authority and accountability being given to the businesses," Pfizer says. Companies expect deal to close by year-end (2"The Tan Sheet" July 22, 2002, p. 8)...

You may also be interested in...



Pfizer/Pharmacia OTC Motion Sickness Stronghold Could Make FTC Queasy

Pfizer's acquisition of Pharmacia likely will draw antitrust regulatory scrutiny to one of the combined firm's smallest product lines - OTC motion sickness tablets

Bayer Confident CureVac COVID Pact Will Be A Success

CEO Werner Baumann admits he was skeptical at first as to whether the German group had the necessary know-how to manufacture vaccines but the firm's expertise in the development of biotech products has strengthened his belief Bayer can deliver.

EMA Works On Defining Metadata From RWD Sources

As part of its big data initiative, the European Medicines Agency is supporting projects that will help identify appropriate real-world data sources for regulatory decision making.

Topics

UsernamePublicRestriction

Register

LL1132098

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel